A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP

Michael O'Dwyer

A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP

Michael O'Dwyer

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Other Item
Volume	101
Publication status	Published - 1 Jun 2016

Cite this

@misc{0d91ffd91a0e46a4a16bd2603c14bf97,

title = "A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP",

author = "Michael O'Dwyer",

year = "2016",

month = jun,

day = "1",

language = "English (Ireland)",

volume = "101",

type = "Other",

}